Amanda Baumann is a senior engineering and healthcare technology leader with extensive experience in medical devices and orthopedic robotics. She began her engineering career at Johnson & Johnson, where she worked on neurovascular stroke treatment devices, building a strong foundation in customer-focused innovation. In 2008, she joined MAKO Surgical Corp., which became part of Stryker in 2013, designing orthopedic implants, and applications for the Mako Robotic Arm. With Stryker she advanced into leadership roles supporting all aspects of the Mako SmartRobotics research and development. Today, she serves as Senior Director, Ortho Clinical Solutions, leading clinical and application software efforts in hip, knee, and shoulder robotics.

Maria Berkman, MD, MBA, is a partner at Vensana Capital. Prior to Vensana, Maria was the Head of MedTech at Broadview Ventures and Managing Director of Longview Ventures—affiliate funds dedicated to cardiovascular disease and stroke. Maria currently serves on the boards of Alleviant Medical and Vensana Innovation, and previously served as Chair of AtaCor Medical (partnered with Abbott), and on the boards of Vectorious (acquired), Apama (acquired), CardiAQ (acquired), Remedy Therapeutics (acquired), Capricor (IPO), and Lyra Therapeutics (IPO). Prior to her venture career, Maria was a management consultant with Monitor Group and trained at Mass General Brigham’s Newton Wellesley Hospital. Outside her venture career, Maria serves on the Board of the Boston Museum of Science and as a member of the Acquisitions Circle at the Institute of Contemporary Art / Boston.

Adam is CEO of Alleviant Medical, Inc., a clinical-stage company developing minimally invasive therapies for heart failure patients. Previously, he was CEO and Co-Founder of TVA Medical, Inc. (acquired by BD), where they developed endovascular technology for patients in kidney failure. Prior, he held various commercial and R&D roles at Coalescent Surgical (acquired by Medtronic), MedicalCV, and Computer Motion (acquired by Intuitive Surgical). Adam also serves as a board member or advisor at select medtech companies. He received his BSE magna cum laude in biomedical engineering from Rensselaer Polytechnic Institute and his MSE in bioengineering from the University of Washington.

As CEO of Resonant Link Medical, I am leading the effort to make wireless power and data transfer the foundation for intelligent, connected implants. Our Aurion WPT platform enables Intelligent Focal Technology (IFT), a new generation of smaller, smarter, and site-specific medical devices that deliver targeted therapy and diagnostics with greater effectiveness and less invasiveness. My experience spans the full MedTech value chain, from product strategy and commercialization to fundraising, team building, and corporate development. I am deeply motivated by the potential of technology to improve outcomes for undertreated patient populations and redefine how medicine is delivered.

Successful, profit driven healthcare executive with over 20 years progressive experience in management, sales, clinical, and business development. Visionary leader and team player with stellar track record of superior performance in sales productivity, team building, customer relationship building, and account development. Notable interpersonal skills with a capacity to reach all levels of field personnel, management, and physicians. Multi dimensional, innovative strategist focused on consistent achievement of objectives. Recognized for an outstanding work ethic, integrity, and commitment to corporate goals and directives. Eternal optimist with a focused "can-do" attitude.

Jan founded Arboretum on the premise that innovation is key to delivering value in healthcare, a principle she developed working in the medical device industry for over two decades. Her investments focus on promising medical technologies that enable meaningful healthcare system savings while maintaining great clinical outcomes. Jan has led and held board roles in more than 25 investments across six funds including notable exits with HandyLab (acquired by BD), Esperion (Nasdaq: ESPR), NxThera (acquired by Boston Scientific), CardioMEMS (acquired by St. Jude Medical), and NeuMoDx (acquired by QIAGEN). Jan served on the National Venture Capital Association’s Board of Directors from 2015-2020 and in her last year, was the Board Chair. As chair, she prioritized industry-wide diversity initiatives and was instrumental in driving small business access to CARES Act financial assistance programs early in the COVID pandemic. In 2020 she testified at the US Senate on “Expanding American Entrepreneurship Outside Traditional Hubs”. Jan was recently awarded the Venture Vanguard Award by the NVCA (2023). Previous awards include: USA Top Women Dealmakers Award (2021), MichBusiness Women Leaders Hall of Fame (2020), Crain’s 100 Most Influential Women (2021, 2016), and as Crain’s Newsmaker of the Year (2015). She earned a BS in Bioengineering from the University of California at Berkeley and an MBA from the Wharton School at the University of Pennsylvania.

Virginia is Vice President of Exploration at Edwards Lifesciences, where she builds external partnerships globally to advance breakthrough innovation. She has a track record of delivering innovation to patients, with roles spanning medical device, pharmaceutical and nutrition businesses. Virginia has focused on advancing innovation, with R&D, Program Management, and Business Development leadership roles at Stryker, Abbott, and Johnson & Johnson. She chairs the Cornell Biomedical Engineering Advisory Council, is an AIMBE Fellow, and is a co-founder of MedtechWomen. She holds B.S. and M.Eng. degrees in Mechanical Engineering from Cornell and a Ph.D. in Mechanical Engineering from Stanford.

Senior Conference Director at Cambridge Innovation Institute.

Robert J. Greenberg MD, PhD, joined huMannity (formerly Alfred Mann Foundation) in 1998, was elected Chairman of the Board of Directors in 2004, and became its Chairman and CEO in 2021. He was a co-founder and former CEO and Chairman of the Board of Second Sight Medical Products, Inc. (formerly NASDAQ: EYES) in Los Angeles, California. Dr. Greenberg is a leader in the field of neural prosthetics—having developed and brought to market the world’s most advanced implantable neural stimulator at the time, the Argus II visual prostheses, to treat retinitis pigmentosa, a form of blindness. At Second Sight, he also oversaw the successful development and human implantation of a wireless cortical visual prosthesis, the Orion, which has the potential to treat nearly all forms of blindness and other brain diseases. Dr. Greenberg was also an Independent Director at Pulse Biosciences (NASDAQ: PLSE), a company developing therapies based on nanosecond pulsed electric field technologies for oncology and dermatology applications. He was previously a medical reviewer at the FDA’s Office of Device Evaluation. Since 2001, he has also been the Chairman of the Board of Directors at the Southern California Biomedical Council, a nonprofit trade association supporting the healthcare industry in the Greater Los Angeles region. Dr. Greenberg is the recipient of numerous honors and awards, has over 260 issued US patents and over 100 international patents, and has published over 60 articles. He received MD and PhD degrees from The Johns Hopkins School of Medicine in Baltimore, Maryland. He has been a member of the New York Academy of Sciences, a fellow of the American Institute for Medical and Biological Engineering, a fellow of the National Academy of Inventors, and a fellow of the IEEE.

David has 25 years of healthcare experience evaluating Medical Device, Life Science Tool, Diagnostic and Digital Health companies and advising boards on strategic and financial direction. Prior to founding Gilmartin Capital, David was a Managing Director at Morgan Stanley and Head of Morgan Stanley’s medical technology equity research practice for the last 15-years. He was a top ranked analyst at Morgan Stanley and in the Institutional Investor (II) Medical Supplies & Devices annual poll. Before joining Morgan Stanley, David was a partner and top ranked medical technology analyst at Thomas Weisel Partners and a founding member of the healthcare practice. David received a BA in healthcare policy with honors from the University of Pennsylvania. David serves as an advisor to Equalize Health, a non-profit that is developing medical devices for underserved populations. He lives outside of San Francisco with his wife Lynn, daughter Olivia, son Jack, and dog Tucker. David is a struggling guitar player, recovering a cappella singer, and he loves the mountains in any season.

Geoff Martha is Chairman and CEO of Medtronic, a global leader in healthcare technology. Under his leadership, 95,000 Medtronic employees deliver transformative medical innovations to alleviate pain, restore health and extend life for 79 million patients annually. A driven and innovative executive, Geoff was named CEO in April 2020 after joining Medtronic in 2011 and holding various enterprise-level leadership roles in strategy, corporate development, and business oversight. He previously spent nearly two decades in senior leadership roles at GE Healthcare and GE Capital and has been recognized multiple times by Modern Healthcare as one of the 100 Most Influential People in Healthcare. Geoff is passionate about the intersection of healthcare and technology. He actively participates in global business organizations, including the Business Roundtable, the World Economic Forum’s International Business Council, and the U.S.-China Business Council. He also serves as Treasurer of AdvaMed and Chairman of the Minnesota Business Partnership. He is on the board of NextEra Energy, a Trustee for the Asia Society, and on several non-profit boards including the Medtronic Foundation, the Northside Achievement Zone (NAZ), and YMCA of the North. Geoff holds a finance degree from Penn State University.x`

Ramin Mousavi is a dynamic and seasoned healthcare executive, currently serving as the President, CEO, and a member of the Board of Directors at CathWorks, a digital health company revolutionizing the diagnosis and treatment of cardiovascular disease through advanced computational science and artificial intelligence. He has an outstanding history of building high-performing organizations and achieving exceptional results in the medical device and high-tech industries—from early development to global commercialization of breakthrough and transformational innovations. Professional Background He is currently the President and Chief Executive Officer (CEO) of CathWorks, an innovative global medical device company dedicated to improving patient care. Mousavi's career spans various leadership roles across multiple industries. Prior to his tenure at CathWorks, he led the patient monitoring and digital health portfolio at Baxter International. He also held significant positions at Edwards Lifesciences, Panasonic Avionics, and Rockwell Collins, gaining extensive experience in general management, marketing, strategy, product development, and commercialization. Education Mousavi holds a dual Bachelor of Science degree in Computer and Electrical Engineering from the University of California, Irvine. He furthered his education with an MBA from the Paul Merage School of Business at UC Irvine. He completed a Healthcare Executive Leadership program for Business Innovation in Global Healthcare from Harvard Business School. Community Engagement & Recognitions An active alumnus, Mousavi has contributed to the UC Irvine community by serving as Chair of the Dean’s Leadership Circle at the Paul Merage School of Business. He has been instrumental in expanding the DLC Grant Initiative, supporting students, faculty, and the local business community. He is currently the Vice-Chair of the Dean’s Advisory Board.

Maggie Nixon joined Capstan Medical in 2022, after spending more than two decades at Intuitive Surgical, where she held a wide range of increasing leadership roles across R&D, clinical development, quality, and regulatory. Known for bringing teams together to solve complex problems, Maggie helped guide technologies from early concept through commercialization. Before joining Capstan, Maggie led Intuitive’s China operations and strategy, helping expand the company’s presence and capabilities in one of the world’s fastest-growing healthcare markets. At Capstan, Maggie is focused on building a company that moves quickly, tackles hard problems, and works closely with physicians & engineers to determine how heart-valve therapies can be re-imagined using robotics, cutting-edge implant and catheter technology, and AI-based imaging.

Josh is a founder and managing partner of CHV and a member of the firm’s Investment Committee. He is actively involved in all aspects of fund management, including investments and capital raising, and has led investments in the medical device, women’s health, and molecular diagnostics markets for over 20 years. Josh led CHV’s investments in Allegro Diagnostics (acquired by Veracyte), Vortex Medical (acquired by AngioDynamics), SevenOaks Biosystems (acquired by Medline), Sera Prognostics (NASD: SERA), Saphena Medical (acquired), Conformal Medical (acquired by WL Gore), Brixton Biosciences, EyeCool Therapeutics, Epitel, and Esperto Medical. He has represented CHV on the boards of each of those companies. From 2000 to 2007, Josh was the Managing Partner of Catalyst Health and Technology Partners, LLC., an organization that made early-stage investments in healthcare and technology-focused companies. During that time, Josh led investments in Novazyme Pharmaceuticals (acquired by Genzyme (Sanofi)), BioTrove (acquired by Life Technologies (Thermo Fisher), and Biocius Life Sciences (acquired by Agilent Technologies). He served as the Chairman of BioTrove and a director of Biocius Life Sciences, and a board observer to Novazyme Pharmaceuticals. From 1997 to 2000, he was a manager at the Lucas Group, a boutique strategy-consulting firm, where he led engagements advising healthcare, life science, and technology-based companies. Prior to that, Josh co-founded, managed, and built a new business unit at Russelectric, a privately held engineering technology firm that is now part of Siemens. Josh previously held project and engineering management positions at Pratt & Whitney Aircraft, focused on the control system of the USAF F-22 fighter engine. Josh received an M.B.A. from the Harvard Business School and a B.E. in Electrical Engineering and Mathematics from Vanderbilt University.

James is an experienced medical device executive with over three decades of expertise in strategic planning, commercial execution, fundraising, and M&A. He currently serves as the CEO and President of Conformal Medical, a device company focused on the development of the AcuFORM designed for left atrial appendage occlusion. Reinstein served as President, CEO, and board member at several other early-stage companies where he raised over $300M in capital funding and transacted multiple companies. Earlier in his career, Reinstein also served as Senior Vice President and Chief Commercial Officer for LivaNova and spent several years at Boston Scientific in multiple roles and geographies. Since 2015, he has served as a General Partner with Palo Alto Medtech Advisors. Reinstein holds a bachelor’s in business administration, marketing, from the University of Georgia and completed executive management training at INSEAD in Fontainebleau, France.

Alexander is a partner at Endeavour Vision, leading investments in healthcare technologies across multiple therapeutic areas. He brings over two decades of business and strategy experience in medical device and high-growth companies. He currently represents Endeavour Vision on the boards of FLEX Vascular and HealthJoy. He previously served on the boards of Relievant MedSystems (acquired by Boston Scientific), Gynesonics (acquired by Hologic), V-Wave (acquired by Johnson & Johnson), VertiFlex (acquired by Boston Scientific), and Rapid Micro Biosystems (NASDAQ: RPID), and co-led the firm’s investment in Kestra Medical Technologies (NASDAQ: KMTS). Prior to joining the Endeavour Vision team, Alexander spent nine years with Biosensors International Group, an interventional cardiology company, where he served as vice president of business development. He previously worked with LogiSpring Ventures, MicroStrategy, and McKinsey & Co. Alexander holds an MBA from INSEAD and a BSFS in economics from Georgetown University.

Amrinder Singh is a Partner at Vensana Capital and joined the firm in 2021. Amrinder has nearly two decades of medtech operating and investing experience, ranging from engineering, corporate strategy, and venture capital investing. Prior to Vensana Capital, Amrinder was a Senior Investment Director at Medtronic Ventures where he supported new investments in the medtech and digital health spaces, providing operational and board management support to portfolio companies. Prior to his investment career, Amrinder led Business Development & Strategy for Medtronic’s care management services, helping to shape the vision for Medtronic's value-based healthcare strategy. Amrinder started his career at Medtronic within the Corporate Strategy group. Before joining Medtronic, Amrinder held product management and engineering positions at Thoratec Corporation. Amrinder graduated from University of California, Davis in Biosystems Engineering and earned his MBA from Northwestern University, Kellogg School of Management.

Darshana is a Founder and Managing Partner of CHV and a member of the firm’s Investment Committee. She is actively involved in all aspects of the fund, including investments and capital raising, and has led investments in the medical device, women’s health and diagnostics markets for over 15 years. Darshana led CHV’s investments in Augmenix (acquired by Boston Scientific), nVision Medical (acquired by Boston Scientific), Maxwell Health (acquired by SunLife), Aria CV, PanTher Therapeutics, AtaCor Medical, Instylla, Avive, Rejoni and Venova Medical. She has represented CHV on the Boards of each of those companies. Prior to joining CHV in 2007, Darshana was an Investigator at Vertex Pharmaceuticals, and an integral part of drug development programs in oncology, metabolic disease, and immunology. Previously she worked at Genome Therapeutics, a Massachusetts-based biotechnology company and at the Dana Farber Cancer Institute. Darshana currently serves as an advisor of the Deshpande Center for Technological Innovation at MIT, (a foundation that helps MIT students and faculty commercialize breakthrough technologies and inventions), as a Board Director of The New England Venture Capital Association (NEVCA) and as a lead advisor to the Portfolia FemTech fund (an investment fund designed for women). Darshana received an M.P.A. from Harvard University, an M.A. in Cell and Molecular Biology from Boston University, and a B.S. in Biochemistry from Bombay University in Bombay, India.